Skip to content
Screener

Foghorn Therapeutics FHTX Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$16.1MBeat by $9.3M
EPS-$0.10Beat by $0.15
Revenue estimate$6.8M
EPS estimate-$0.25

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$7.1M
EPS estimate-$0.22

FAQ

When did Foghorn Therapeutics report Q2 2026 earnings?
Foghorn Therapeutics (FHTX) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Foghorn Therapeutics's Q2 2026 revenue and EPS?
Foghorn Therapeutics reported revenue of $16.1M and eps of $-0.10 for Q2 2026.
Did Foghorn Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $6.8M by $9.3M. EPS beat the consensus estimate of $-0.24 by $0.14.
How did Foghorn Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 113.0% from $7.6M a year earlier and eps grew 64.3% from $-0.28.
Where can I find Foghorn Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-053817) and the 10-Q periodic report (0001628280-26-053819) directly on SEC EDGAR. The filing index links above go to sec.gov.